Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.71 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | NPC1 | O15118 | 4/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.62 |
| ▸ | MEN1 | O00255 | 8/20 | 0.62 |
| ▸ | RAB9A | P51151 | 3/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11533429 | 0.91 | CYP2C9 (0.65) | SMN1; SMN2LMNANPC1KMT2AMEN1 | |
| SCHEMBL2730689 | 0.86 | SMN1; SMN2 (0.85) | SMN1; SMN2LMNANPC1KMT2AMEN1 | |
| SCHEMBL5933202 | 0.84 | SMN1; SMN2 (0.63) | SMN1; SMN2LMNANPC1KMT2AMEN1 | |
| SCHEMBL5932688 | 0.84 | CYP1A2 (0.55) | SMN1; SMN2LMNANPC1KMT2AMEN1 | |
| SCHEMBL12466491 | 0.84 | CYP1A2 (0.55) | SMN1; SMN2LMNANPC1KMT2AMEN1 | |
| SCHEMBL171709 | 0.84 | KMT2A (0.66) | SMN1; SMN2LMNANPC1KMT2AMEN1 | |
| SCHEMBL8602062 | 0.84 | CYP2C9 (0.59) | SMN1; SMN2LMNANPC1KMT2AMEN1 | |
| SCHEMBL13049648 | 0.84 | SMN1; SMN2 (1.00) | SMN1; SMN2NPC1KMT2AMEN1RAB9A | |
| SCHEMBL28909751 | 0.83 | NPC1 (0.69) | SMN1; SMN2LMNANPC1KMT2AMEN1 | |
| SCHEMBL5933146 | 0.83 | SMN1; SMN2 (0.61) | SMN1; SMN2LMNANPC1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2139860-A2 | DERIVATIVES OF THE AMINATED HYDROXYQUINOLINE CLASS FOR TREATING CANCERS | Biopharmed Société à Responsabilité Limitée (FR) | 2010-01-06 | — | — | EP | claimed |
| WO-2008135671-A2 | DERIVATIVES OF THE AMINATED HYDROXYQUINOLINE CLASS FOR TREATING CANCERS | BIOPHARMED Société à responsabilité limitée (FR) | 2008-11-13 | — | — | WO | claimed |
| EP-4145995-A1 | PESTICIDAL COMPOSITIONS AND RELATED METHODS | CJB Applied Technologies, LLC (US) | 2023-03-15 | — | — | EP | disclosed |
| CN-114040912-A | Compounds for the treatment of kinase-dependent disorders | 埃克塞里艾克西斯公司 | 2022-02-11 | — | — | CN | disclosed |
| WO-2021226566-A1 | PESTICIDAL COMPOSITIONS AND RELATED METHODS | CJB APPLIED TECHNOLOGIES, LLC (US) | 2021-11-11 | — | — | WO | disclosed |
| EP-3709804-A1 | PESTICIDAL COMPOSITIONS AND RELATED METHODS | CJB Applied Technologies, LLC (US) | 2020-09-23 | — | — | EP | disclosed |
| CN-102300847-A | PPAR agonist compositions and methods of use thereof | — | 2011-12-28 | — | — | CN | disclosed |
| EP-2139860-A2 | DERIVATIVES OF THE AMINATED HYDROXYQUINOLINE CLASS FOR TREATING CANCERS | Biopharmed Société à Responsabilité Limitée (FR) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008135671-A2 | DERIVATIVES OF THE AMINATED HYDROXYQUINOLINE CLASS FOR TREATING CANCERS | BIOPHARMED Société à responsabilité limitée (FR) | 2008-11-13 | — | — | WO | disclosed |
| US-20060088786-A1 | Rewritable optical information recording medium, recording and reproducing methods, as well as recording and reproducing apparatus | MITSUI CHEMICALS, INC. (JP) | 2006-04-27 | — | — | US | disclosed |
| EP-1484191-A1 | REWRITABLE OPTICAL INFORMATION RECORDING MEDIUM AND RECORDING/REPRODUCING METHOD, RECORDING/REPRODUCING DEVICE | Sony Corporation (JP) | 2004-12-08 | — | — | EP | disclosed |
| EP-0298419-A2 | A protein partial degradation product, process for preparing it and its use | Katayama Chemical Works Co., Ltd. (JP) | 1989-01-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060088786-A1 | Rewritable optical information recording medium, recording and reproducing methods, as well as recording and reproducing apparatus | ALPG, TRPC6, GNRHR | SMN1; SMN2 3024/4885LMNA 1161/4885NPC1 4636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.